不同剂量坦索罗辛与比卡鲁胺联合曲普瑞林内分泌治疗前列腺癌患者近、远期临床疗效分析  

Short-Term and Long-Term Clinical Efficacy of Different Dosages of Tamsulosin and Bicalutamide Combined with Triptorelin in the Treatment of Prostate Cancer

作　　者：刘建刚[1] 李坚勇[1] 陈旭[1] LIU Jiangang;LI Jianyong;CHEN Xu(The First People's Hospital of Liangshan Yi Autonomous Prefecture,Xichang,Sichuan,China 615000)

机构地区：[1]四川省凉山彝族自治州第一人民医院

出　　处：《中国药业》2019年第15期61-63,共3页China Pharmaceuticals

基　　金：四川省科技计划项目[2015SZ0230-7]

摘　　要：目的探讨不同剂量坦索罗辛与比卡鲁胺联合曲普瑞林内分泌治疗前列腺癌(PCa)患者的近、远期临床疗效。方法选取医院2008年1月至2013年1月收治的PCa患者128例,均予以常规临床基础治疗,并在此基础上予以坦索罗辛、比卡鲁胺联合曲普瑞林内分泌治疗,根据坦索罗辛使用剂量的不同分为对照组(58例,低剂量)和观察组(70例,高剂量)。结果治疗后,两组患者血清前列腺特异性抗原(PSA)水平、国际前列腺症状(IPSS)和疼痛视觉模拟评分(VAS)均较治疗前明显下降,且观察组均显著低于对照组(P<0.05);观察组临床总有效率为77.14%,显著高于对照组的48.28%(P<0.05);两组患者生活质量均较治疗前明显改善(P<0.05),且观察组明显优于对照组(P<0.05);治疗后,观察组患者5年生存率为62.86%,显著高于对照组的44.83%(P<0.05);对照组与观察组患者不良反应发生率无显著差异(17.24%比20.00%,χ^2=0.158,P=0.691)。结论高剂量坦索罗辛与比卡鲁胺联合曲普瑞林治疗PCa,更有利于改善临床症状,提高临床疗效、生活质量和远期生存率,且具有一定的安全性,值得作为保守治疗PCa的首选方案。Objective To investigate the short-term and long-term clinical efficacy of different dosages of tamsulosin combined with bicalutamide and triptorelin in the treatment of prostate cancer(PCa).Methods Totally 128 patients with PCa admitted to our hospital from January 2008 to January 2013 were selected.All patients were given routine basic clinical treatment,on this basis,they were treated with tamsulosin,bicalutamide and triptorelin.However,according to the dosage of tamsulosin,all the patients were divided into the control group(58 cases,low-dosage)and the observation group(70 cases,high-dosage).Results After treatment,the levels of serum prostate-specific antigen(PSA),International Prostate Symptom Score(IPSS)and Visual Analogue Score(VAS)in the two groups were significantly lower than those before treatment,and those in the observation group were significantly lower than those in the control group(P<0.05).The total clinical effective rate of the observation group was 77.14%,which was significantly higher than 48.28%of the control group(P<0.05).The quality of life of patients in the two groups was significantly improved compared with that before treatment(P<0.05),and that in the observation group was significantly better than that in the control group(P<0.05).After treatment,the 5-year survival rate of the patients in the observation group was 62.86%,which was significantly higher than 44.83%in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the control group and the observation group(17.24%vs.20.00%,χ^2=0.158,P=0.691).Conclusion High-dosage tamsulosin combined with bicalutamide and triptorelin is more beneficial to improve the clinical symptoms,clinical efficiency,quality of life and long-term survival rate of patients with PCa,and has a certain degree of safety.It is worthy of being the first choice for conservative treatment of patients with PCa.

关 键 词：坦索罗辛 给药剂量 比卡鲁胺 曲普瑞林 前列腺癌 近期疗效 远期疗效 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]